Invitae Corporation (NYSE:NVTA) was founded in 2010, formerly known as Locus Development, Inc., changed to the current Invitae Corporation in 2012, and IPO on the New York Stock Exchange on February 12, 2015. The company’s headquarters are located in San Francisco, California, USA. There are 1,500 full-time employees.
Invitae Corporation (NVTA):
Gene sequencing, a field that is not well known to people, came into people’s field of vision in 2013 due to the news “Angelina Jolie removes both breasts to prevent breast cancer”, and provided Julie with genetic testing. The most likely breast cancer is the gene sequencing company Wanji Genetics (NASDAQ: MYGN). Invitae and Wanji Genetics are in the same field. Other listed companies in the industry include: Illumina (ILMN), Shangju Medical Industry (HOLX), Thermo Fisher Scientific (TMO), CareDx (CDNA), Applied Genetic Technologies (AGTC) and Daan Gene (SZ002030), a domestic A-share listed company.
Invitae focuses on the study of gene sequences, and strives to unsecret all gene sequences to achieve the greatest medical application, helping people to better enjoy a healthy life. Invitae uses an integrated combination of laboratory procedures, software tools and information functions for doctors and patients to process samples containing patient DNA, analyze their specific genetic variation information, and generate test reports. Invitae also provides a single diagnostic service, including about 200 genes, which are mainly used for the detection of various genetic diseases related to cancer. Others include cardiovascular diseases, blood genetic diseases, neurological diseases and children’s genetic diseases. In addition, NVTA also provides a family gene information composition sharing solution, which can be achieved through a web page or an APP. It enables doctors and patients to search for various genes and variants in order to find other genetic genes.
Introduction to the gene sequencing industry:
With the decline in the price of gene sequencing services, the total amount of the gene information service industry will increase exponentially, and the generation, analysis and storage of gene information will achieve unprecedented development. According to data from the OMM research group of Johns Hopkins University School of Medicine, more than 4,000 genetic symptoms related to gene mutations have been discovered. Sequencing these genes is beneficial to the diagnosis and treatment of genetic diseases. In the foreseeable future, humans will not only sequence a single or a limited number of genes.
Genes are the cornerstone of modern medicine, and gene sequencing will benefit the general public. In fact, everyone carries some mutated genes in their bodies. Recessive genetic diseases will affect the health of offspring. Gene mutations will also affect the effects of drugs and treatments. In the modern medical system, everyone will have their own genetic information and become an important reference for clinical medicine.
According to statistics from United Health Group Inc, the molecular diagnostics market in the United States was approximately US$5 billion in 2010, of which genetic sequencing accounted for approximately 60%. As of December 2014, genestests.org estimated that more than 40,000 genes have been sequenced from 650 laboratories worldwide. It is estimated that by 2021, the molecular diagnostics market in the United States will reach 9 billion US dollars, and the gene sequencing market share will remain at 60%.
Invitae company introduction:
NVTA has an office and clinical laboratory in San Francisco, and a clinical laboratory in Santiago, Chile. Invitae has an interdisciplinary team of 161 people, including: bioinformatics, clinical science, genetics, genetic consultants, web and software engineers, image processing engineers, etc. NVTA’s development goals are clear: first attack the sick and newborn market, and then move to the healthy market (health care, prevention). The goal is divided into three stages:
- Gene sequencing: strive to bring down the price of gene sequencing, and at the same time strive to expand the market.
- Gene management: establish a safe and reliable genome management system to generate and store a large amount of personal genetic information.
- Genome network. Under the premise of obtaining permission from the owner of genetic information, we help patients share genetic information. Genetic information is more valuable because of sharing, and will jointly promote the development of science and medicine.
invitae is committed to providing cheaper and more convenient gene sequencing services, and at the same time, it is committed to providing all-in-one gene sequencing services to increase utility value. They sold their first gene sequencing report in November 2013. Each report is charged 1,500 US dollars, and customers can choose one or several gene sequencing, or all types. As of the end of the third quarter of 2014, the company has provided services to more than 2,000 customers, 80% of which have signs of hereditary cancer. Invitae’s hereditary cancer service has two options (BRCA1 and BRCA2), hereditary breast cancer gene template containing 7 genes, hereditary colon cancer gene template containing 14 genes, and pancreatic cancer gene template containing 17 genes. Or a global cancer gene template containing 29 cancer genes. The fee for each service is $1,500.
Advantages of invitae’s gene sequencing service:
- Low price: one price includes all sequencing
- Fast: only three weeks from sampling to report issuance
- Flexible: Customers can independently choose the type of sequencing and gene template
- Extension: Gene template selection, repeated report
- High quality: NVTA gene expert team can produce high-quality sequencing results
The core concept of NVTA:
- Patients should have ownership of their genetic information
- Genetic information is more valuable due to sharing
- Healthcare professionals are the basis for guiding and interpreting gene sequencing activities
- Reducing the price of gene sequencing services can increase clinical application value and personal utility
NVTA risk warning:
- The company is in an early stage of loss
- The company needs to invest in the construction of basic platform facilities before the market. If it does not obtain enough sequencing service orders, the company will lose money
- If medical insurance does not cover the company’s gene sequencing services, revenue and business development will be affected
- Industry competition
- The procurement of laboratory equipment and consumables relies on a few manufacturers, and there is only a single manufacturer in some fields. If they lose them, they may face failure to find a replacement in time
- Facing regulatory and legal issues including the FDA, if the FDA regulates gene sequencing services as medical equipment, it will have a serious impact on the company’s business and financial status.